| 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma (NCT03121456) | Centre Antoine Lacassagne | 2017-10-13 |
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03123393) | Calithera Biosciences, Inc | 2017-10-10 |
| Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma (NCT03200015) | Hospital Universitario Dr. Jose E. Gonzalez | 2017-10-01 |
| To Decrease Fatigue With Light Therapy (NCT03242902) | The Netherlands Cancer Institute | 2017-09-20 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (NCT03255096) | Hoffmann-La Roche | 2017-08-28 |
| Chidamide With R-CHOP Regimen for DLBCL Patients (NCT03201471) | First Affiliated Hospital of Zhejiang University | 2017-08-20 |
| Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing (NCT03226704) | National Cancer Institute (NCI) | 2017-08-14 |
| Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03072771) | Washington University School of Medicine | 2017-08-01 |
| Cyclophosphamide and Alemtuzumab In Lymphoma (NCT03132584) | Dana-Farber Cancer Institute | 2017-07-30 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL (NCT03213977) | Fujian Medical University | 2017-07-10 |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma (NCT03576443) | Nordic Lymphoma Group | 2017-07-07 |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (NCT03513601) | Mingzhi Zhang | 2017-07-01 |
| Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma (NCT03145064) | BeiGene | 2017-06-30 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT03064867) | Molly Gallogly | 2017-06-26 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (NCT03147885) | Barbara Ann Karmanos Cancer Institute | 2017-06-20 |
| Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma (NCT04661943) | Ou Bai, MD/PHD | 2017-06-01 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) (NCT03104478) | The Lymphoma Academic Research Organisation | 2017-05-09 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL (NCT03465527) | Kosin University Gospel Hospital | 2017-04-13 |
| Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (NCT02981745) | Centaurus Biopharma Co., Ltd. | 2017-04-01 |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (NCT03106428) | MedImmune LLC | 2017-03-29 |
| Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL (NCT03259529) | St. Petersburg State Pavlov Medical University | 2017-03-27 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients (NCT03028103) | Epizyme, Inc. | 2017-03-27 |
| Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (NCT03129828) | Prof. Dr. Clemens Schmitt | 2017-03-17 |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (NCT03036904) | Weill Medical College of Cornell University | 2017-02-06 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (NCT02483000) | Fred Hutchinson Cancer Center | 2017-02-01 |
| Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma (NCT03042247) | Marco Picardi | 2017-01-24 |
| Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients (NCT03079947) | Peking Union Medical College Hospital | 2017-01-01 |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma (NCT03376958) | Zhengzhou University | 2017-01-01 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (NCT02951156) | Pfizer | 2016-12-16 |
| RICE-ibrutinib in Relapsed DLBCL (NCT02955628) | Singapore General Hospital | 2016-12-13 |
| Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma (NCT03399747) | Asan Medical Center | 2016-12-07 |
| The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas (NCT03000738) | Peking Union Medical College Hospital | 2016-12-01 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma (NCT03383406) | Asan Medical Center | 2016-12-01 |
| Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL (NCT02747732) | Meirav Kedmi MD | 2016-12-01 |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02763319) | Incyte Corporation | 2016-11-28 |
| The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma (NCT03022123) | Hebei Medical University Fourth Hospital | 2016-11-01 |
| Refractory Diffuse Large B-cell Lymphoma (NCT03664336) | Hospices Civils de Lyon | 2016-11-01 |
| Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (NCT02900651) | Novartis Pharmaceuticals | 2016-10-03 |
| A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas (NCT02700022) | UNC Lineberger Comprehensive Cancer Center | 2016-10-01 |
| Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma (NCT02951728) | Ruijin Hospital | 2016-10-01 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma (NCT02871869) | Xinjiang Medical University | 2016-09-01 |
| Role of CX3CR1-expressing Cells in Hematologic Malignancy (NCT02885623) | Saint Vincent's Hospital, Korea | 2016-08-01 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma (NCT02855359) | Seagen Inc. | 2016-08-01 |
| MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (NCT02549651) | MedImmune LLC | 2016-07-13 |
| R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL (NCT03151044) | FENG Ji-feng | 2016-07-01 |
| Reduced Chemotherapy in Low Risk DLBCL (NCT02752815) | Ruijin Hospital | 2016-06-14 |
| Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL (NCT02564744) | Debiopharm International SA | 2016-06-05 |
| A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02734771) | Patrick Reagan | 2016-06-01 |
| CyBeR Association in Relapsed/Refractory DLBCL (NCT02758925) | University Hospital, Caen | 2016-06-01 |
| Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02708732) | Hoffmann-La Roche | 2016-05-31 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (NCT02793583) | TG Therapeutics, Inc. | 2016-05-25 |
| RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (NCT03485118) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2016-05-12 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma (NCT02756247) | Memorial Sloan Kettering Cancer Center | 2016-05-09 |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma (NCT02733380) | Henan Cancer Hospital | 2016-05-01 |
| Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT (NCT02692248) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2016-04-07 |
| Chidamide Plus R-CHOP in Elderly DLBCL (NCT02753647) | Ruijin Hospital | 2016-04-01 |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (NCT02399085) | MorphoSys AG | 2016-03-29 |
| Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (NCT02660710) | UNC Lineberger Comprehensive Cancer Center | 2016-03-01 |
| DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma (NCT02815397) | Rush University Medical Center | 2016-02-01 |
| A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma (NCT02702141) | Seagen Inc. | 2016-02-01 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044) | Juno Therapeutics, a Subsidiary of Celgene | 2016-01-06 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920) | University of Arizona | 2015-12-16 |
| Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma (NCT02420210) | University of Chicago | 2015-11-01 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma (NCT02481310) | Northwestern University | 2015-10-28 |
| Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma (NCT02449265) | Wuhan University | 2015-10-01 |
| An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT02752204) | University of Birmingham | 2015-10-01 |
| The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma (NCT02449278) | Wuhan University | 2015-10-01 |
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (NCT02393157) | New York Medical College | 2015-08-21 |
| Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (NCT02753062) | Asan Medical Center | 2015-08-01 |
| Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) (NCT02531308) | Rush University Medical Center | 2015-07-01 |
| CNS Prophylaxis in Diffuse Large B-cell Lymphoma (NCT02777736) | Czech Lymphoma Study Group | 2015-07-01 |
| Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma (NCT02595242) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2015-06-01 |
| Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02391116) | Bayer | 2015-05-08 |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas (NCT02401048) | Pharmacyclics LLC. | 2015-05-01 |
| A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL (NCT02542111) | Ruijin Hospital | 2015-05-01 |
| Bortezomib Maintenance in High Risk DLBCL (NCT01965977) | Samsung Medical Center | 2015-04-08 |
| Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma (NCT02474550) | Ajou University School of Medicine | 2015-04-01 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (NCT02361346) | Molecular Templates, Inc. | 2015-02-01 |
| R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis (NCT02842931) | National Research Center for Hematology, Russia | 2015-02-01 |
| A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL (NCT02323230) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2015-01-01 |
| New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement (NCT02329080) | International Extranodal Lymphoma Study Group (IELSG) | 2014-12-01 |
| Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients (NCT02374424) | Fondazione Italiana Linfomi - ETS | 2014-11-05 |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02227251) | Karyopharm Therapeutics Inc | 2014-11-01 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL (NCT02142530) | Massachusetts General Hospital | 2014-10-01 |
| Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ (NCT02128061) | The Lymphoma Academic Research Organisation | 2014-08-01 |
| Safety Study of SGN-CD70A in Cancer Patients (NCT02216890) | Seagen Inc. | 2014-08-01 |
| High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma (NCT02531841) | University Hospital Freiburg | 2014-07-01 |
| Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation (NCT02252146) | Idera Pharmaceuticals, Inc. | 2014-06-01 |
| The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study (NCT05169203) | Herlev Hospital | 2014-01-01 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692) | Merck Sharp & Dohme LLC | 2013-11-22 |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (NCT01846390) | Canadian Cancer Trials Group | 2013-10-01 |